2026-04-14T08:33:59Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4663612026-03-28T08:23:33Zcom_2072_98col_2072_378192

Predictive and prognostic value of total tumor load in sentinel lymph nodes in breast cancer patients after neoadjuvant treatment using one-step nucleic acid amplification : the NEOVATTL study Vieites, B. López-García, M. Martín-Salvago, M.D. Ramírez Tortosa, César Luis Rezola, R. Sancho, M. López Vilaró, Laura Villardell, F. Burgués, Octavio Fernández-Rodriguez, B. Alfaro, L. Peg, Vicente Breast cancer Disease-free survival Neoadjuvant systemic therapy OSNA Sentinel lymph node Total tumor load Altres ajuts: Sysmex España S.L. Objective: To evaluate the predictive and prognostic value of total tumor load (TTL) in sentinel lymph nodes (SLNs) in patients with infiltrating breast cancer after neoadjuvant systemic therapy (NST). Methods: This retrospective multicenter study used data from a Spanish Sentinel Lymph Node database. Patients underwent intraoperative SLN biopsy after NST. TTL was determined from whole nodes using a one-step nucleic acid amplification (OSNA) assay and defined as the total sum of CK19 mRNA copies in all positive SLNs. Cox-regression models identified independent predictive variables, which were incorporated into a nomogram to predict axillary non-SLN metastasis, and identified prognostic variables for incorporation into a disease-free survival (DFS) prognostic score. Results: A total of 314 patients were included; most had no lymph node involvement prior to NST (cN0; 75.0% of patients). Most received chemotherapy with or without biologic therapy (91.7%), and 81 patients had a pathologic complete response. TTL was predictive of non-SLN involvement (area under the concentration curve = 0.87), and at a cut-off of 15,000 copies/µL had a negative predictive value of 90.5%. Nomogram parameters included log (TTL + 1), maximum tumor diameter and study-defined NST response. TTL was prognostic of disease recurrence and DFS at a cut-off of 25,000 copies/µL. After a 5-year follow-up, DFS was higher in patients with ≤ 25,000 copies/µL than those with. 2021 Article https://ddd.uab.cat/record/271906 urn:10.1007/s12094-020-02530-4 urn:oai:ddd.uab.cat:271906 urn:scopus_id:85100055751 urn:articleid:16993055v23n7p1377 urn:pmid:33517542 urn:pmc-uid:8192368 urn:pmcid:PMC8192368 urn:oai:pubmedcentral.nih.gov:8192368 urn:oai:egreta.uab.cat:publications/499d7936-39cd-4eaf-b555-0a99ed8163b2 eng Clinical & translational oncology ; Vol. 23 Núm. 7 (july 2021), p. 1377-1385 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/ application/pdf